Time | Session |
---|---|
14:15
14:25
|
STOP-ACEi Study
Plenary Halls 2 & 3
|
14:25
14:30
|
Q and A
Plenary Halls 2 & 3
|
14:30
14:40
|
DETERMINANTS OF THE EFFECTS OF SGLT2i ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNEY TRIAL
Plenary Halls 2 & 3
|
14:40
14:45
|
Q and A
Plenary Halls 2 & 3
|
14:45
14:55
|
SPARSENTAN REDUCES PROTEINURIA IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN): INTERIM RESULTS OF THE PROTECT STUDY
Plenary Halls 2 & 3
|
14:55
15:00
|
Q and A
Plenary Halls 2 & 3
|
15:00
15:10
|
RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL OF ARTESUNATE IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
|
15:10
15:15
|
Q and A
Plenary Halls 2 & 3
|